Sjoquist, Katrin M <br/><br/>
Hope, quality of life, and benefit from treatment in women having chemotherapy for platinum-resistant/refractory recurrent ovarian cancer: the gynecologic cancer intergroup symptom benefit study.  [electronic resource] 

 -  The oncologist  2013 
 - 1221-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1549-490X 
<br/><br/><label>Standard No.: </label>10.1634/theoncologist.2013-0175  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Anxiety--etiology<br/>Carcinoma, Ovarian Epithelial<br/>Depression--etiology<br/>Drug Resistance, Neoplasm<br/>Female<br/>Hope<br/>Humans<br/>Longitudinal Studies<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Neoplasms, Glandular and Epithelial--drug therapy<br/>Organoplatinum Compounds--pharmacology<br/>Ovarian Neoplasms--drug therapy<br/>Prognosis<br/>Quality of Life<br/>Surveys and Questionnaires<br/>Treatment Outcome